PAREXEL International GmbH, Berlin, Germany.
Novartis Pharmaceuticals Corporation, 1 Health Plaza, Building 315, 04-4230E, East Hanover, NJ, 07936, USA.
Clin Drug Investig. 2017 May;37(5):465-472. doi: 10.1007/s40261-017-0497-0.
Osilodrostat (LCI699) is an adrenal steroidogenesis inhibitor currently in late-phase clinical development as a potential treatment for Cushing's disease. This study evaluated the inhibitory effect of osilodrostat on the pharmacokinetics of probe substrates of the cytochrome P450 (CYP) enzymes CYP1A2, CYP2C19, CYP2D6, and CYP3A4.
Healthy adult volunteers received single-dose cocktail probe substrates [caffeine (100 mg), omeprazole (20 mg), dextromethorphan (30 mg), and midazolam (2 mg)] followed by a 6-day washout. Subjects then received a single dose of osilodrostat 50 mg followed by a single dose of cocktail probe substrates.
Nineteen of twenty subjects (ten were male) completed the study. Mean age, body weight, and body mass index were 41.8 years, 73.0 kg, and 24.4 kg/m. Geometric mean ratio of the area under the concentration-time curve from time zero to the last measureable concentration and 90% confidence intervals of probe substrate exposure with osilodrostat were: caffeine (CYP1A2 probe substrate), 2.33 (2.10-2.59); omeprazole (CYP2C19), 1.91 (1.74-2.11); dextromethorphan (CYP2D6), 1.48 (1.34-1.63); and midazolam (CYP3A4/5), 1.50 (1.41-1.60). Corresponding values for geometric mean ratio of maximum plasma concentration (90% confidence interval) for the change in substrate exposure were 1.07 (0.988-1.15), 1.61 (1.40-1.84), 1.35 (1.21-1.50), and 1.47 (1.32-1.62).
Osilodrostat is a moderate inhibitor of CYP1A2 and CYP2C19 and a weak inhibitor of CYP2D6 and the most clinically important CYP enzyme, CYP3A4. Osilodrostat is unlikely to significantly increase the exposures of other medications cleared by CYP3A4. These findings are clinically relevant given that Cushing's disease is a chronic condition often requiring multiple medications and that most other therapies have significant drug interaction potential.
奥昔司他(LCI699)是一种正在进行后期临床开发的肾上腺甾体生成抑制剂,有望用于治疗库欣病。本研究评估了奥昔司他对细胞色素 P450(CYP)酶 CYP1A2、CYP2C19、CYP2D6 和 CYP3A4 的探针底物药代动力学的抑制作用。
健康成年志愿者接受单次剂量鸡尾酒探针底物[咖啡因(100mg)、奥美拉唑(20mg)、右美沙芬(30mg)和咪达唑仑(2mg)],随后进行 6 天的洗脱期。然后,受试者接受单次奥昔司他 50mg 剂量,随后接受单次鸡尾酒探针底物剂量。
20 名受试者中有 19 名(10 名为男性)完成了研究。平均年龄、体重和体重指数分别为 41.8 岁、73.0kg 和 24.4kg/m²。奥昔司他的探针底物暴露的 AUC(从零时到最后可测量浓度)和 90%置信区间的几何均数比值和 90%置信区间为:咖啡因(CYP1A2 探针底物),2.33(2.10-2.59);奥美拉唑(CYP2C19),1.91(1.74-2.11);右美沙芬(CYP2D6),1.48(1.34-1.63);咪达唑仑(CYP3A4/5),1.50(1.41-1.60)。相应的最大血浆浓度(90%置信区间)变化的几何均数比值为底物暴露的变化,为 1.07(0.988-1.15)、1.61(1.40-1.84)、1.35(1.21-1.50)和 1.47(1.32-1.62)。
奥昔司他是 CYP1A2 和 CYP2C19 的中度抑制剂,是 CYP2D6 和最重要的临床 CYP 酶 CYP3A4 的弱抑制剂。奥昔司他不太可能显著增加经 CYP3A4 清除的其他药物的暴露量。这些发现具有临床意义,因为库欣病是一种慢性疾病,通常需要多种药物治疗,而大多数其他治疗方法都有显著的药物相互作用潜力。